News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
update
The US regulatory scientists who oversee biopharmaceuticals appear to be getting the funding they asked for after politicians pass a $1.2tr (€882bn) Government spending plan for fiscal 2014.
Immunogen has inked a deal to use probodies from CytomX with its own cytotoxics and linker technology, to create probody-drug conjugates (PDCs).
Shire has divested its regenerative skingraft product Dermagraft to Organogenesis citing a loss of financial incentive due to new Medicare ruling regarding reimbursement.
The evaluation of Genmab’s Duobody platform for the discovery and development of bispecific antibodies strengthens Eli Lilly’s biologics programme, the firm says.